Are you Dr. Jain?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St Ste 21-100
Suite 1000
Chicago, IL 60611Phone+1 312-695-0990
Summary
- Dr. Sarika (Das) Jain, MD is an oncologist in Chicago, Illinois. She is currently licensed to practice medicine in Illinois and New York. She is an Assistant Professor at Northwestern University.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2009 - 2012
- University of MichiganResidency, Internal Medicine, 2006 - 2009
- Southern Illinois University School of MedicineClass of 2006
Certifications & Licensure
- IL State Medical License 2012 - 2020
- NY State Medical License 2009 - 2014
Clinical Trials
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
- Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
- BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx Start of enrollment: 2014 May 21
- Join now to see all
Publications & Presentations
PubMed
- 98 citationsConcordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.Young Kwang Chae, Andrew M. Davis, Sarika Jain, Cesar A. Santa-Maria, Lisa Flaum
Molecular Cancer Therapeutics. 2017-07-01 - 63 citationsPhase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.Ami N. Shah, Lisa Flaum, Irene Helenowski, Cesar A. Santa-Maria, Sarika Jain
Journal for Immunotherapy of Cancer. 2020-02-01 - 95 citationsPhase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapySarika Jain, Ami N. Shah, Cesar A. Santa-Maria, Kalliopi P. Siziopikou, Alfred Rademaker
Breast Cancer Research and Treatment. 2018-05-30